BioXcel Therapeutics, Inc. Retained Earnings
BioXcel Therapeutics, Inc. (BTAI) had Retained Earnings of -$747.50 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$747.50M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$732.78M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$720.09M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$707.55M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$747.50M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$732.78M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$720.09M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$707.55M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$676.64M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$657.45M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$650.20M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$639.34M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$625.69M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$617.39M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$590.60M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$568.34M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$517.86M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$464.34M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$411.55M 10-K · filed 2024-03-22 |
| 2022-09-30 | -$356.74M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$314.93M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$277.26M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$245.79M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$219.66M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$192.85M 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$165.23M 10-Q · filed 2021-05-10 |
| 2020-12-31 | -$138.86M 10-K · filed 2022-03-11 |
| 2020-09-30 | -$117.77M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$93.02M 10-Q · filed 2020-08-14 |
| 2020-03-31 | -$71.60M 10-Q · filed 2020-05-12 |
| 2019-12-31 | -$56.69M 10-K · filed 2021-03-12 |
| 2019-09-30 | -$48.41M 10-Q · filed 2019-11-14 |
| 2019-06-30 | -$39.40M 10-Q · filed 2019-08-06 |
| 2019-03-31 | -$30.92M 10-Q · filed 2019-05-07 |
| 2018-12-31 | -$23.72M 10-K · filed 2020-03-09 |
| 2018-09-30 | -$16.64M 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$11.76M 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$8.73M 10-Q · filed 2018-05-14 |
| 2017-12-31 | -$4.45M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |